Navigation Links
Ranbaxy Develops New Compound for Respiratory Inflammation

Indian generics major, Ranbaxy Laboratories Limited has achieved a significant milestone in its collaboration with GSK.//

The company’s New Drug Discovery Research (NDDR) team has finished the development of a new compound for respiratory inflammation.

As per the recently signed multi-year agreement signed between the two companies in 2003, Ranbaxy will further profile this drug candidate through pre-clinical studies and take it through an Investigational New Drug (IND) application.

Ranbaxy will also be responsible for conducting phase I and phase II clinical studies through to proof of concept. GSK will then have the option to conduct further development through to final commercialization.

Dr Pradip Bhatnagar, Senior Vice President, New Drug Discovery, Ranbaxy, said, "A dynamic collaboration between GSK’s CEEDD and Ranbaxy has been the key for this success. This achievement also reflects the discovery capabilities of Ranbaxy's research team and the growing partnership between the two organizations in the area of NCE research."

Ranbaxy could receive over $100 million in potential milestone payments for a product developed by Ranbaxy and subsequently launched by GSK in multiple indications and up to double digit royalties on worldwide net sales.

Source- BioSpectrum /
'"/>




Page: 1

Related medicine news :

1. Ranbaxy joins hand with Cipla to co-market ciprofloxacin
2. Ranbaxy gets US FDA approval for Lisinopril
3. Ranbaxy Labs Entry Into Anti-Acne Market
4. Ranbaxy trying to make inroads in herbal drugs market
5. Lamivudine Manufactured By Ranbaxy gets the nod from the US FDA
6. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
7. Ranbaxy opens Drug discovery centre in Gurgaon
8. Ranbaxy Laboratories All Set To Export Bird Flu Vaccines
9. SRL Ranbaxy offers quicker bird flu diagnostic test
10. Diagnostic Test Launched by Ranbaxy for En Masse Screening of Bird Flu
11. Ranbaxy Launches Once-a-day Inhaler For Asthma Patients
Post Your Comments:
Breaking Medicine Technology:Circassia Raises GBP15 Million ($25 Million) in Oversubscribed Investment Round 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5Bavarian Nordic A S Half Year Interim Report 2009 13729 1Bavarian Nordic A S Half Year Interim Report 2009 13729 2Bavarian Nordic A S Half Year Interim Report 2009 13729 3Bavarian Nordic A S Half Year Interim Report 2009 13729 4Bavarian Nordic A S Half Year Interim Report 2009 13729 5Bavarian Nordic A S Half Year Interim Report 2009 13729 6Bavarian Nordic A S Half Year Interim Report 2009 13729 7Promising Cancer Research Treatment Breakthrough Seeks Funding for Corroboration of Results 55591 1Promising Cancer Research Treatment Breakthrough Seeks Funding for Corroboration of Results 55591 2ALOKA Announces New ProSound Alpha Series Ultrasound System 55587 1ALOKA Announces New ProSound Alpha Series Ultrasound System 55587 2ALOKA Announces New ProSound Alpha Series Ultrasound System 55587 3